Anal canal cancer clinical practice guidelines in oncology

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 3, Issue 4, 2005, Pages 510-515

  Engstrom, Paul F ^a   Benson III, Al B ^b   Chen, Yi Jen ^c   Choti, Michael A ^d   Dilawari, Raza A ^e   Enke, Charles A ^f   Fakih, Marwan G ^g   Fuchs, Charles ^h   Kiel, Krystyna ^b   Knol, James A ⁱ   Leong, Lucille A ^c   Ludwig, Kirk A ^j   Martin Jr , Edward W ^k   Rao, Sujata ^l   Wasif Saif, M ^m   Saltz, Leonard ⁿ   Skibber, John M ^o   Venook, Alan P ^p   Yeatman, Timothy J ^q  

^a FOX CHASE CANCER CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c City of Hope Cancer Center   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

^f NEBRASKA MEDICAL CENTER   (United States)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

^h Dana Farber/Partners CancerCare   (United States)

ⁱ UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^j DUKE CANCER INSTITUTE   (United States)

^k OHIO STATE UNIVERSITY   (United States)

^l SEATTLE CANCER CARE ALLIANCE   (United States)

^m UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁿ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^o UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^p UNIVERSITY OF CALIFORNIA   (United States)

^q H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

more..

Author keywords

Anal neoplasms; Biopsy; NCCN clinical practice guidelines; Neoplasm staging; Surgery

Indexed keywords

CISPLATIN; FLUOROURACIL; MITOMYCIN;

ANUS CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; CLINICAL TRIAL; CLOACA; FOLLOW UP; HUMAN; MEDICAL SOCIETY; PATIENT MONITORING; RECTUM BIOPSY; REVIEW; SQUAMOUS CELL CARCINOMA; UNSPECIFIED SIDE EFFECT; ANUS TUMOR; ARTICLE; MULTIMODALITY CANCER THERAPY; ONCOLOGY; PATHOLOGY; PRACTICE GUIDELINE; STANDARD;

ANUS NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; MEDICAL ONCOLOGY; NEOPLASM STAGING;

EID: 27744499328     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2005.0026     Document Type: Review

References (8)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Ryan DP, Compton CC, Mayer RJ. Medical Progress: Carcinoma of the anal canal. N Engl J Med 2000;342:792-800.
3. Klencke BJ, Palefsky JM. Anal cancer: an HIV-associated cancer. Hematol Oncol Clin North Am 2003;17:859-872.
4. Greenall MJ, Quan SH, Urmacher C, et al. Treatment of epidermoid carcinoma of the anal canal. Surg Gynecol Obstet 1985;161:509-517.
5. Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996;14:2527-2539.
6. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer; results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997;15:2040-2049.
7. UKCCCR Anal Cancer Trial Working Party. Epidermoid anal cancer: results from the UKCCCR randomized trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet 1996;348:1049-1054.
8. Hung A, Crane C, Delclos M, et al. Cisplatin-based combination modality therapy for anal carcinoma. Cancer 2003;97:1195-1202.